01722nas a2200205   4500000000100000008004100001260000900042653002600051653003500077653001100112653002100123653001400144653002500158100001200183245008700195300001000282490000700292520120300299022001401502       1994                            d  c199410aCommunicable Diseases10aGranulomatous Disease, Chronic10aHumans10aInterferon-gamma10aNeoplasms10aRecombinant Proteins1 aRobak T00a[Biological properties and clinical applications of interferon gamma (IFN-gamma)].  a19-290 v253 a<p>Interferon-gamma (IFN-gamma) is produced by activated T cells and probably by NK cells. Its production can be induced by mitogens, antigens and other molecules. IFN-gamma interacts with cells by binding to specific membrane receptors. IFN-gamma--1b is an Escherichia coli--derived recombinant DNA product, which has biological activity identical to natural human IFN-gamma. This IFN type is a more potent immunomodulator than IFN-alpha and IFN-beta. Long term treatment with a therapeutic dosage of IFN-gamma--1b produces a significant reduction in the incidence of serious infections in patients with chronic granulomatous disease. This cytokine can be also useful in the treatment of patients with visceral leishmaniasis, Epstein-Barr virus infections, lepromatous leprosy and other infectious diseases. Phase I and II studies have demonstrated it to be capable of producing antitumor effects, especially in metastatic renal cell carcinoma and some hematologic malignancies. Clinical trials have suggested efficacy of IFN-gamma in the treatment of severe atopic dermatitis and rheumatoid arthritis. The most common adverse reactions are fever, headaches and erythema at the injection site.</p>  a0001-5814